Loading
AMEXHealthcareMedical - Instruments & Supplies
Latest quote
$1.12
−$0.01 · -0.88%
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Regular session
$1.12
−$0.01 · -0.88%
Regular session · ET · Market data may be delayed.
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Day range
Current $1.12
52-week range
Current $1.12
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
67
Undervalued
Sentiment
55
Mixed
Risk
74
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Day range
Current $1.12
52-week range
Current $1.12
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32.38M USD | 26.92M USD | 26.77M USD | 28.15M USD | 35.02M USD |
| Cost of goods sold | 15.31M USD | 12.32M USD | 11.91M USD | 9.68M USD | 11.79M USD |
| Gross profit | 17.07M USD | 14.59M USD | 14.86M USD | 18.47M USD | 23.23M USD |
| Research and development | 9.38M USD | 9.76M USD | 10.27M USD | 10.56M USD | 10.2M USD |
| Selling, general, and administrative | 30.29M USD | 29.57M USD | 26.43M USD | 26.69M USD | 25.92M USD |
| Operating expenses | 39.18M USD | 39.33M USD | 36.7M USD | 37.25M USD | 36.12M USD |
| Interest income | 467K USD | 694K USD | 1.1M USD | 484K USD | — |
| Interest expense | — | — | — | — | 10.07K USD |
| Depreciation and amortization | 1.56M USD | 969K USD | 595K USD | 429K USD | 106K USD |
| Operating income | −22.11M USD | −24.74M USD | −21.84M USD | −18.78M USD | −12.89M USD |
| Net income | −21.64M USD | −24.05M USD | −20.71M USD | −18.29M USD | −10.72M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.50
212.50% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.86M0.00%2.3T USD0.03%$379.43-0.42%
iShares Russell 2000 ETFIWM1.88M0.00%78.56B USD0.19%$274.73-1.07%
Vanguard Extended Market ETFVXF1.42M0.00%95.4B USD0.05%$231.25-0.96%
iShares Russell 2000 Growth ETFIWO729.96K0.01%14.25B USD0.24%$350.23-1.45%
Vanguard Russell 2000 ETFVTWO562.4K0.00%18B USD0.06%$110.93-1.14%
iShares Micro-Cap ETFIWC244.61K0.02%1.33B USD0.60%$180.87-1.36%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM140K0.12%116.75M USD0.73%$15.77-1.25%
Vanguard Russell 2000 Growth ETFVTWG110.85K0.01%1.7B USD0.06%$255.73-1.37%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
